It has beendemonstrated that removal or neutralization of anti-β1-AR exertsbeneficial therapeutic effects on dilated cardiomyopathy [24]; this treatmentstrategy may also be applicable to patients with CCM. Here, ADRB1 is linked to cerebral cavernous malformation.